Press Release

Rigicon has expanded its UNITED Clinical Study investigator team, appointing Dr. Rafael Carrion as Principal Investigator for the USF/TGH site.

Rigicon has officially launched patient enrollment in the AUSOME Study (Artificial Urinary Sphincter Outcomes Multicenter Evaluation) in the UK.

Rigicon’s clinical study on the Testi10™ testicular prosthesis, published in the International Journal of Impotence Research, shows a 99.8% survival rate over 54 months.

Rigicon’s study on ContiReflex^® for male incontinence shows a 98% survival rate at 18 months, with minimal revisions, showcasing its safety and effectiveness.

Rigicon’s Rigi10™ study shows a 99.2% survival rate at 36 months, with less than 1% revision surgery, low infection risk, and high patient satisfaction.

Rigicon’s Infla10^® study shows comparable revision-free survival rates to other devices, with low infection rates and high mechanical stability over 2-3 years.

Rigicon’s ContiClassic^® study highlights a 93.2% survival rate at 12 months, with no infections or major complications, confirming its safety in male SUI treatment.

Introducing the HL-LEVINE Combo Prosthesis Tool: Rigicon’s latest innovation for efficient penile implant surgeries, co-developed by top urologists.

New study confirms the safety and high satisfaction of Rigicon Infla10^® Three-Piece Inflatable Penile Prosthesis, a reliable ED treatment option.

Rigicon launches CE-marked ContiClassic^® & ContiReflex^® Artificial Urinary Sphincter Systems, offering advanced solutions for urinary incontinence treatment.

Rigicon’s new generation malleable penile prosthesis Rigi10™ receives FDA 510(k) clearance, alongside the successful launch of the inflatable penile prosthesis Infla10® in Europe, Asia Pacific and Latin America.